We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




AI Tool Accurately Predicts Cancer Three Years Prior to Diagnosis

By HospiMedica International staff writers
Posted on 24 Aug 2023

Over the past five decades, there has been a surge in cases of a specific type of esophageal and stomach cancer - esophageal adenocarcinoma (EAC) and gastric cardia adenocarcinoma (GCA). More...

Both cancers have high fatality rates, although preventive measures can make a difference. Screenings can detect pre-cancerous changes, such as Barrett’s esophagus, often identified in individuals with long-standing gastroesophageal reflux disease (GERD). Although guidelines suggest screening for high-risk patients, many healthcare providers remain unfamiliar with this recommendation. Now, a new artificial intelligence (AI) tool offers accurate predictions for these forms of esophageal and stomach cancer at least three years in advance of a diagnosis.

Researchers at Michigan Medicine (Ann Arbor, MI, USA) have developed an automated tool integrated into the electronic health record (EHR). This tool has the potential to bridge the awareness gap between healthcare providers and patients with an elevated risk of developing EAC and GCA. The researchers employed a specific type of AI for analyzing data related to EAC and GCA rates across more than 10 million U.S. veterans in order to develop and validate the Kettles Esophageal and Cardia Adenocarcinoma prediction tool, or K-ECAN for short.

K-ECAN leverages readily accessible data from the EHR, including patient demographics, weight, prior diagnoses, and routine lab results, to gauge an individual's risk of developing EAC and GCA. Outperforming published guidelines and previously validated prediction tools, K-ECAN accurately predicts cancer at least three years ahead of a diagnosis. Integrating this AI tool into the EHR could automatically notify healthcare providers about patients at a higher risk of developing EAC and GCA.

“Symptoms of GERD, like heartburn, are an important risk factor for esophageal adenocarcinoma,” said Joel Rubenstein, M.D., M.S., professor of internal medicine at Michigan Medicine. “But most people with GERD symptoms will never develop esophageal adenocarcinoma and gastric cardia adenocarcinoma. In addition, roughly half of the patients with this form of cancer never experienced prior GERD symptoms at all. This makes K-ECAN particularly useful because it can identify people who are at elevated risk, regardless of whether they have GERD symptoms or not.”

Related Links:
Michigan Medicine 


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
LED Surgical Lamp
ACEMST35/57
New
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The tool could help healthcare providers more accurately identify patients who have higher CVD risk (Photo courtesy of 123RF)

New Tool Predicts Cardiovascular Disease Risk More Accurately

Cardiovascular disease (CVD) affects over 127 million adults in the U.S. and remains a leading cause of illness and death. Accurate prediction of CVD risk is essential for guiding early interventions,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.